Kura Oncology Reports First Quarter 2024 Financial Results
Kura Oncology Reports First Quarter 2024 Financial Results
05-02-2024
– Breakthrough Therapy Designation for ziftomenib in NPM1-mutant AML –
– Registration-directed trial of ziftomenib in NPM1-mutant AML on track to complete enrollment by mid-2024 –
– Positive preliminary combination data for ziftomenib in NPM1-mutant and KMT2A-rearranged AML –
– First patient dosed with KO-2806 and cabozantinib in renal cell carcinoma –
–
– Management to host webcast and conference call today at
“Ziftomenib continues to demonstrate a best-in-class safety and efficacy profile as well as optimal pharmaceutical properties, which we believe will enable it to become a cornerstone of therapy in acute leukemias and beyond,” said
Recent Highlights
- Breakthrough Therapy Designation for ziftomenib in NPM1-mutant AML – Last month, the
U.S. Food and Drug Administration (FDA) granted BTD to ziftomenib for the treatment of relapsed/refractory (R/R) NPM1-mutant AML. FDA granted BTD based on data from Kura’s ongoing KOMET-001 trial of ziftomenib in patients with R/R NPM1-mutant AML. BTD is awarded for a drug that treats a serious or life-threatening condition and may demonstrate substantial improvement on one or more clinically significant endpoints over available therapies. - Registration-directed trial of ziftomenib in NPM1-mutant AML nearing completion – Kura remains on track to complete enrollment of 85 patients in its KOMET-001 registration-directed trial of ziftomenib in NPM1-mutant R/R AML by mid-2024. In the Phase 1 trial, ziftomenib demonstrated a 35% CR rate and 45% overall response rate in 20 heavily pretreated patients with NPM1-mutant AML treated at the recommended Phase 2 dose. NPM1-mutant AML accounts for approximately 30% of new AML cases annually and represents a disease of significant unmet need for which no approved targeted therapy exists.
- Positive preliminary combination data for ziftomenib in NPM1-mutant and KMT2A-rearranged AML – In
January 2024 , Kura reported preliminary data from the KOMET-007 dose-escalation trial of ziftomenib in combination with venetoclax/azacitidine or cytarabine/daunorubicin (7+3) in patients with NPM1-mutant or KMT2A-rearranged AML. As of the data cutoff onJanuary 11, 2024 , all five newly diagnosed patients treated with ziftomenib and 7+3 achieved a complete remission (CR) with full count recovery, for a CR rate of 100%. The overall response rate among the 15 R/R patients treated with ziftomenib and venetoclax/azacitidine was 53%. Continuous daily dosing of ziftomenib at 200 mg was well tolerated. No differentiation syndrome events of any grade were reported, and no dose-limiting toxicities, evidence of QTc prolongation, drug-drug interactions or additive myelosuppression were observed. As of the data cutoff, 16 of the first 20 patients remained on trial, including all 11 NPM1-mutant patients. - Dose escalation continues in KOMET-007 combination trial of ziftomenib – To date, the 400 mg dose of ziftomenib has been cleared in three of the four cohorts in the KOMET-007 trial: 1) in combination with venetoclax/azacitidine in R/R NPM1-mutant AML, 2) in combination with venetoclax/azacitidine in R/R KMT2A-rearranged AML and 3) in combination with 7+3 in newly diagnosed adverse risk NPM1-mutant AML. Enrollment at the 600 mg dose is ongoing in all three cohorts. Enrollment continues at the 400 mg dose in combination with 7+3 in newly diagnosed adverse risk KMT2A-rearranged AML.
- First patients dosed in KOMET-008 combination trial of ziftomenib – In February, Kura began dosing patients in its KOMET-008 trial of ziftomenib in combination with additional standards of care, including the FLT3 inhibitor gilteritinib, FLAG-IDA or LDAC, for the treatment of R/R NPM1-mutant or KMT2A-rearranged AML. Preclinical data for ziftomenib in combination with FLT3 inhibitors demonstrate strong synergistic effects compared to either single agent alone. Roughly half of patients with R/R NPM1-mutant AML have co-occurring FLT3 mutations, and the prognosis for these patients is poor.
- First patients dosed with KO-2806 and cabozantinib in renal cell carcinoma – In March, Kura announced dosing of the first patient with KO-2806, the Company’s next-generation farnesyl transferase inhibitor (FTI), in combination with cabozantinib in clear cell renal cell carcinoma, just four months after dosing the first patients with KO-2806 as a monotherapy in the FIT-001 dose-escalation trial. The Company remains on track to dose the first patient in combination with adagrasib in KRASG12C-mutated non-small cell lung cancer by the middle of this year, as dose escalation of KO-2806 as a monotherapy continues in parallel.
Financial Results
- Research and development expenses for the first quarter of 2024 were
$36.3 million , compared to$25.2 million for the first quarter of 2023. - General and administrative expenses for the first quarter of 2024 were
$18.2 million , compared to$11.4 million for the first quarter of 2023. - Net loss for the first quarter of 2024 was
$49.5 million , compared to a net loss of$34.1 million for the first quarter of 2023. This included non-cash share-based compensation expense of$8.5 million , compared to$6.8 million for the same period in 2023. - As of
March 31, 2024 , Kura had cash, cash equivalents and short-term investments of$527 million , compared to$424 million as ofDecember 31, 2023 . This includes net proceeds of approximately$145.8 million from the Company’s private placement inJanuary 2024 . - Based on its operating plan, management expects that cash, cash equivalents and short-term investments will fund current operations into 2027.
Forecasted Milestones
- Complete enrollment of 85 patients in the KOMET-001 registration-directed trial of ziftomenib in NPM1-mutant R/R AML by mid-2024.
- Identify the recommended Phase 2 dose of ziftomenib in combination with venetoclax and azacitidine by mid-2024.
- Identify the recommended Phase 2 dose of ziftomenib in combination with 7+3 by mid-2024.
- Initiate Phase 1b expansion study of ziftomenib in combination with standards of care, including venetoclax/azacitidine in newly diagnosed NPM1-mutant or KMT2A-rearranged AML, in the second half of 2024.
- Submit an investigational new drug application for ziftomenib in a solid tumor indication and present preclinical data at a medical meeting in the second half of 2024.
- Dose the first patients with KO-2806 and adagrasib in KRASG12C-mutated non-small cell lung cancer by mid-2024.
- Complete enrollment of two expansion cohorts in KURRENT-HN and identify the optimal biologically active dose of tipifarnib and alpelisib by the end of 2024.
- Present data from the KURRENT-HN trial of tipifarnib in combination with alpelisib in PIK3CA-dependent head and neck squamous cell carcinoma (HNSCC) in the first half of 2025.
Conference Call and Webcast
Kura’s management will host a webcast and conference call at
About
Forward-Looking Statements
This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety and therapeutic potential of Kura’s product candidates, ziftomenib, tipifarnib and KO-2806, progress and expected timing of Kura’s drug development programs and clinical trials and submission of regulatory filings, the presentation of data from clinical trials, plans regarding regulatory filings and future clinical trials, the regulatory approval path for tipifarnib, the strength of Kura’s balance sheet and the sufficiency of cash, cash equivalents and short-term investments to fund its current operating plan to 2027. Factors that may cause actual results to differ materially include the risk that compounds that appeared promising in early research or clinical trials do not demonstrate safety and/or efficacy in later preclinical studies or clinical trials, the risk that Kura may not obtain approval to market its product candidates, uncertainties associated with performing clinical trials, regulatory filings, applications and other interactions with regulatory bodies, risks associated with reliance on third parties to successfully conduct clinical trials, the risks associated with reliance on outside financing to meet capital requirements, and other risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. You are urged to consider statements that include the words “may,” “will,” “would,” “could,” “should,” “believes,” “estimates,” “projects,” “promise,” “potential,” “expects,” “plans,” “anticipates,” “intends,” “continues,” “designed,” “goal,” or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties the Company faces, please refer to the Company's periodic and other filings with the
| Statements of Operations Data | ||||||||
| (unaudited) | ||||||||
| (in thousands, except per share data) | ||||||||
| Three Months Ended | ||||||||
| 2024 | 2023 | |||||||
| Operating Expenses: | ||||||||
| Research and development | $ | 36,268 | $ | 25,192 | ||||
| General and administrative | 18,184 | 11,374 | ||||||
| Total operating expenses | 54,452 | 36,566 | ||||||
| Other income, net | 4,927 | 2,497 | ||||||
| Net loss | $ | (49,525 | ) | $ | (34,069 | ) | ||
| Net loss per share, basic and diluted | $ | (0.59 | ) | $ | (0.50 | ) | ||
| Weighted average number of shares used in computing net loss per share, basic and diluted | 83,905 | 68,403 | ||||||
| Balance Sheet Data | ||||||||
| (unaudited) | ||||||||
| (in thousands) | ||||||||
| 2024 | 2023 | |||||||
| Cash, cash equivalents and short-term investments | $ | 527,122 | $ | 423,957 | ||||
| Working capital | 505,569 | 397,218 | ||||||
| Total assets | 553,908 | 448,935 | ||||||
| Long-term liabilities | 16,558 | 16,399 | ||||||
| Accumulated deficit | (770,964 | ) | (721,439 | ) | ||||
| Stockholders’ equity | 505,084 | 397,273 | ||||||
Contacts
Investors:
Executive Vice President, Investor Relations & Corporate Communications
(858) 500-8833
pete@kuraoncology.com
Media:
Associate Director, Investor Relations & Corporate Communications
(858) 500-8822
alexandra@kuraoncology.com
Source: Kura Oncology, Inc.